Consolidated Balance Sheets - USD ($)	Dec. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 15,045,000	$ 28,918,000
Prepaid expenses and other current assets	1,381,000	593,000
Total Current Assets	16,426,000	29,511,000
Property and equipment, net	367,000	607,000
Right of Use Asset	419,000	0
Deposits and other assets	23,000	23,000
Total Assets	17,235,000	30,141,000
Current Liabilities:
Accounts payable	2,315,000	1,034,000
Accrued expenses	1,776,000	919,000
Accrued employee benefits	935,000	1,332,000
Deferred rent	0	99,000
Lease liability	249,000	0
Total Current Liabilities	5,275,000	3,384,000
Deferred rent - Long term	0	302,000
Lease liability - Long term	473,000	0
Total Liabilities	5,748,000	3,686,000
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized;120,000 issued and outstanding	12,544,000	12,296,000
Stockholders' Equity:
Common stock, $0.001 par value; 200,000,000 shares authorized, 16,808,758 issued and 16,806,430 outstanding and 15,484,411 issued and 15,482,083 outstanding	17,000	15,000
Additional paid-in capital	232,580,000	230,754,000
Accumulated deficit	(235,537,000)	(219,461,000)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	1,821,000	17,068,000
Non-controlling interest	(2,878,000)	(2,909,000)
Total Stockholders' (Deficit) Equity	(1,057,000)	14,159,000
Total Liabilities and Stockholders' Equity	17,235,000	30,141,000
Series B Preferred Stock [Member]
Stockholders' Equity:
Series B convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 7,638 issued and outstanding and 9,161 issued and outstanding	4,761,000	5,760,000
Total Stockholders' (Deficit) Equity	$ 4,761,000	$ 5,760,000